The content on this site is intended for healthcare professionals only
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
22 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Jun 2021
ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHS...
Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake ...
15 Jun 2021
Developments in metastatic hormone-sensitive prostate cancer
Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria...
11 Jun 2021
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with sel...
Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
9 Jun 2021
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men wi...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
9 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Jun 2021
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Dr Neal Shore and Prof Oliver Sartor
4 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
4 Jun 2021
